The Role of Chemotherapy in the Treatment of Kaposi's Sarcoma
- *Corresponding Author:
- Dr. Essadi Ismail
Service d'oncologie médicale à l'hopital militaire d'instruction Mohamed V, 10100, Rabat, Maroc
Tel : (+212) 661168987
E-mail: [email protected]
Received Date: April 23, 2011; Accepted Date: July 20, 2011; Published Date: July 22, 2011
Citation: Essadi I, Sbitti Y, Ichou M, Errihani H (2011) The Role of Chemotherapy in the Treatment of Kaposi's Sarcoma. J Cancer Sci Ther 3: 145-148. doi:10.4172/1948-5956.1000077
Copyright: © 2011 Essadi I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Kaposi’s sarcoma (KS) is an opportunistic tumor proliferation Multicenter cells derived from lymphatic endothelium, infected with human herpes virus 8 (HHV-8). It is a heterogeneous disease distribution, which can be linked to poor prognosis. HHV-8 infection and immunosuppression are essential to its development [1,2]. These two elements are constant in the four clinical-epidemiological forms of KS: classical form, originally described by Moritz Kaposi typically affecting elderly men of Mediterranean, the endemic presence in Southern Africa, the epidemic form in patients infected HIV, and, finally, the MK complicating iatrogenic immunosuppression, particularly after organ transplantation . This work exposes the real place of chemotherapy in adult patients with Kaposi sarcoma, among the available therapeutic means.